Migratory Joint Swelling: Diagnostic Approach and Management

Immediate Diagnostic Priorities

The American Heart Association suggests that acute rheumatic fever is the most critical diagnosis to consider, as migratory polyarthritis involving large joints is a hallmark major manifestation 2
The American College of Rheumatology recommends that patients with migratory polyarthritis affecting multiple large joints require urgent rheumatology referral within 6 weeks and immediate evaluation to exclude acute rheumatic fever, disseminated gonococcal infection, and Lyme disease before initiating treatment 1, 2
Laboratory evaluation must include complete blood count, ESR, CRP, antistreptolysin O titer, throat culture, rheumatoid factor, anti-CCP antibodies, antinuclear antibodies, urinalysis, and transaminases to exclude various diagnoses 1, 2

The American College of Rheumatology recommends that patients with arthritis affecting more than one joint must be referred to and seen by a rheumatologist within 6 weeks of symptom onset, as earlier treatment initiation leads to better outcomes 1

The American College of Rheumatology suggests that the "squeeze test" is essential, and lateral compression of the metatarsophalangeal joints causing pain suggests inflammatory arthritis involving foot joints 1
Assess for joint swelling with associated pain or stiffness, morning stiffness duration, and rapid improvement with NSAIDs to characterize the arthritis 1, 2

The American College of Radiology recommends that if initial radiographs are normal but clinical suspicion remains high, ultrasound with power Doppler, MRI without and with IV contrast, and image-guided aspiration may be necessary to detect early synovitis and bone marrow edema 1, 3, 4

For acute rheumatic fever, the American Heart Association recommends NSAIDs or salicylates for symptomatic relief, systemic glucocorticoids if carditis is present, and penicillin prophylaxis to prevent recurrence 1, 2
For early inflammatory arthritis, the American College of Rheumatology suggests NSAIDs, systemic glucocorticoids, and methotrexate as anchor DMARD if risk factors for persistent disease are present 1